Impact of Age and Comorbidity on Multimodal Management and Survival from Colorectal Cancer : A Population-Based Study
Kellokumpu, I., Kairaluoma, M., Mecklin, J.-P., Kellokumpu, H., Väyrynen, V., Wirta, E.-V., Sihvo, E., Kuopio, T., & Seppälä, T. T. (2021). Impact of Age and Comorbidity on Multimodal Management and Survival from Colorectal Cancer : A Population-Based Study. Journal of Clinical Medicine, 10(8), Article 1751. https://doi.org/10.3390/jcm10081751
Julkaistu sarjassa
Journal of Clinical MedicineTekijät
Päivämäärä
2021Tekijänoikeudet
© 2021 the Authors
This retrospective population-based study examined the impact of age and comorbidity burden on multimodal management and survival from colorectal cancer (CRC). From 2000 to 2015, 1479 consecutive patients, who underwent surgical resection for CRC, were reviewed for age-adjusted Charlson comorbidity index (ACCI) including 19 well-defined weighted comorbidities. The impact of ACCI on multimodal management and survival was compared between low (score 0–2), intermediate (score 3) and high ACCI (score ≥ 4) groups. Changes in treatment from 2000 to 2015 were seen next to a major increase of laparoscopic surgery, increased use of adjuvant chemotherapy and an intensified treatment of metastatic disease. Patients with a high ACCI score were, by definition, older and had higher comorbidity. Major elective and emergency resections for colon carcinoma were evenly performed between the ACCI groups, as were laparoscopic and open resections. (Chemo)radiotherapy for rectal carcinoma was less frequently used, and a higher rate of local excisions, and consequently lower rate of major elective resections, was performed in the high ACCI group. Adjuvant chemotherapy and metastasectomy were less frequently used in the ACCI high group. Overall and cancer-specific survival from stage I-III CRC remained stable over time, but survival from stage IV improved. However, the 5-year overall survival from stage I–IV colon and rectal carcinoma was worse in the high ACCI group compared to the low ACCI group. Five-year cancer-specific and disease-free survival rates did not differ significantly by the ACCI. Cox proportional hazard analysis showed that high ACCI was an independent predictor of poor overall survival (p < 0.001). Our results show that despite improvements in multimodal management over time, old age and high comorbidity burden affect the use of adjuvant chemotherapy, preoperative (chemo)radiotherapy and management of metastatic disease, and worsen overall survival from CRC.
...
![showless](/themes/JYX2//images/showless.png)
![showmore](/themes/JYX2//images/showmore.png)
Julkaisija
MDPI AGISSN Hae Julkaisufoorumista
2077-0383Asiasanat
Julkaisu tutkimustietojärjestelmässä
https://converis.jyu.fi/converis/portal/detail/Publication/68042598
Metadata
Näytä kaikki kuvailutiedotKokoelmat
Lisätietoja rahoituksesta
This research was funded by Government Research Funding, Cancer Foundation Finland, Jane and Aatos Erkko Foundation, Emil Aaltonen Foundation, Finnish Medical Foundation, Sigrid Juselius Foundation, Instrumentarium Science Foundation, iCAN Flagship of the Academy of Finland. Open access funding provided by University of Helsinki.Lisenssi
Samankaltainen aineisto
Näytetään aineistoja, joilla on samankaltainen nimeke tai asiasanat.
-
Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases : a population-based study
Väyrynen, V.; Wirta, E; Seppälä, T.; Sihvo, E.; Mecklin, J-P.; Vasala, K.; Kellokumpu, I. (John Wiley & Sons, 2020)Background This population-based study aimed to examine the incidence, patterns and results of multimodal management of metastatic colorectal cancer. Methods A retrospective population-based study was conducted on patients ... -
Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)
Aho, Sonja; Osterlund, Emerik; Ristimäki, Ari; Nieminen, Lasse; Sundström, Jari; Mäkinen, Markus J.; Kuopio, Teijo; Kytölä, Soili; Ålgars, Annika; Ristamäki, Raija; Heervä, Eetu; Kallio, Raija; Halonen, Päivi; Soveri, Leena-Maija; Nordin, Arno; Uutela, Aki; Salminen, Tapio; Stedt, Hanna; Lamminmäki, Annamarja; Muhonen, Timo; Kononen, Juha; Glimelius, Bengt; Isoniemi, Helena; Lehto, Juho T.; Lehtomäki, Kaisa; Osterlund, Pia (MDPI AG, 2024)The primary tumor location (PTL) is associated with the phenotype, metastatic sites, mutations, and outcomes of metastatic colorectal cancer (mCRC) patients, but this has mostly been studied according to sidedness (right ... -
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study : a double-blind, randomised, placebo-controlled trial
Burn, John; Sheth, Harsh; Elliott, Faye; Reed, Lynn; Macrae, Finlay; Mecklin, Jukka-Pekka; Möslein, Gabriela; McRonald, Fiona E.; Bertario, Lucio; Evans, D. Gareth; Gerdes, Anne-Marie; Ho, Judy W. C.; Lindblom, Annika; Morrison, Patrick J.; Rashbass, Jem; Ramesar, Raj; Seppälä, Toni; Thomas, Huw J. W.; Pylvänäinen, Kirsi; Borthwick, Gillian M.; Mathers, John C.; Bishop, D. Timothy (Elsevier, 2020)Background: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up ... -
KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
Osterlund, Emerik; Ristimäki, Ari; Kytölä, Soili; Kuopio, Teijo; Heervä, Eetu; Muhonen, Timo; Halonen, Päivi; Kallio, Raija; Soveri, Leena-Maija; Sundström, Jari; Keinänen, Mauri; Ålgars, Annika; Ristamäki, Raija; Sorbye, Halfdan; Pfeiffer, Per; Nunes, Luís; Salminen, Tapio; Lamminmäki, Annamarja; Mäkinen, Markus J.; Sjöblom, Tobias; Isoniemi, Helena; Glimelius, Bengt; Osterlund, Pia (Frontiers Media SA, 2022)Background: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been ... -
Retrotransposon insertions can initiate colorectal cancer and are associated with poor survival
Cajuso, Tatiana; Sulo, Päivi; Tanskanen, Tomas; Katainen, Riku; Taira, Aurora; Hänninen, Ulrika A.; Kondelin, Johanna; Forsström, Linda; Välimäki, Niko; Aavikko, Mervi; Kaasinen, Eevi; Ristimäki, Ari; Koskensalo, Selja; Lepistö, Anna; Renkonen-Sinisalo, Laura; Seppälä, Toni; Kuopio, Teijo; Böhm, Jan; Mecklin, Jukka-Pekka; Kilpivaara, Outi; Pitkänen, Esa; Palin, Kimmo; Aaltonen, Lauri A. (Nature Publishing Group, 2019)Genomic instability pathways in colorectal cancer (CRC) have been extensively studied, but the role of retrotransposition in colorectal carcinogenesis remains poorly understood. Although retrotransposons are usually ...
Ellei toisin mainittu, julkisesti saatavilla olevia JYX-metatietoja (poislukien tiivistelmät) saa vapaasti uudelleenkäyttää CC0-lisenssillä.